Rubra Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 29 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.60 Cr
- Revenue Growth 4.08%
- Profit Growth 41.97%
- Ebitda 5.82%
- Net Worth 23.54%
- Total Assets 11.98%
About Rubra Pharmaceuticals
Rubra Pharmaceuticals Limited (RPL) is a Public Limited Indian Non-Government Company incorporated in India on 31 May 1995 and has a history of 29 years and eight months. Its registered office is in Na, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹9.60 Cr.
Kapil Gupta, Narender Gupta, and Nirupa Gupta serve as directors at the Company.
Company Details
-
Location
Na, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24200TG1995PLC020538
-
Company No.
020538
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
31 May 1995
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Rubra Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kapil Gupta
|
Director | 02-Jan-2003 | Current |
|
Narender Gupta
|
Director | 31-May-1995 | Current |
|
Nirupa Gupta
|
Director | 31-May-1995 | Current |
Financial Performance of Rubra Pharmaceuticals.
Rubra Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.08% increase. The company also saw a substantial improvement in profitability, with a 41.97% increase in profit. The company's net worth Soared by an impressive increase of 23.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rubra Pharmaceuticals?
In 2022, Rubra Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Divya Agro Roller Flour Mills Private LimitedKapil Gupta and Narender Gupta are mutual person
-
Varka Labs Private Limited
Kapil Gupta is a mutual person
Charges (Loans)
₹96.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Maharashtra : 9.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Jul 2013 | Bank Of Maharashtra | ₹9.60 Cr | Open |
How Many Employees Work at Rubra Pharmaceuticals?
Unlock and access historical data on people associated with Rubra Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rubra Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rubra Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.